Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05288751

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder
  • Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment
  • Have an active prescription for buprenorphine-naloxone (Suboxone)

Exclusion criteria

  • Prescription for an amphetamine would exclude patients from the abstinence-based CM, but they could participate in the attendance-only CM.
  • Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.

Treatment and study plan

Contingency Management

Behavioral

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.

Primary outcomes

  1. Preliminary efficacy of CM on clinical outcomes: Visit Frequency

    Time frame: 30 days post-intervention

    Number of completed clinical visits per patient during the CM program.

  2. Preliminary efficacy of CM on clinical outcomes: Urine toxicology

    Time frame: 30 days post-intervention

    Percentage of UDS results that are negative for stimulants during the CM intervention period.

  3. Feasibility of CM for OUD in primary care: Recruitment

    Time frame: 30 days post-intervention

    percentage of patients invited to participate enroll in the treatment intervention.

  4. Feasibility of CM for OUD in primary care: Retention

    Time frame: 30 days post-intervention

    Of those patients who enroll in the intervention study, the percent that complete the CM intervention period.

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Contingency Management as a Treatment for Opioid Use Disorder and Stimulant Use Disorder in a Primary Care Setting

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 21, 2022
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.